ClinicalTrials.gg
RecruitingNCT04165070Updated Oct 29, 2026

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

A Phase 1/2 interventional study of Pembrolizumab and Carboplatin in Carcinoma, Non-Small-Cell Lung, sponsored by Merck Sharp & Dohme LLC. Recruiting at 47 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2019; still recruiting 6 years 10 months later.
Updated Oct 29, 2026First site in Canada1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc — 14 open to participants now, 26 under way, 18 of them phase 3. Carcinoma, Non-Small-Cell Lung · Merck & Co., Inc.

Planned enrollment
26th of 88
450 · median 149
Started
2019
with 8 others
Phase 1/2
4 of 91
1 open now
Primary completion
2032-02
later than 17 of 25 live
Registered
58th of 91
by date

Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 26th largest by planned enrollment of the 88 interventional ones that give a count, is one of 9 that started in 2019, is one of 4 in phase 1/2, reaches primary completion later than 17 of the 25 other live ones, and was the 58th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

14 of the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC.

This study is one of the pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

Read the detailed description

The master screening protocol is MK-3475-U01 (KEYMAKER-U01) - NCT04165798

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has - or cytologically-confirmed diagnosis of Stage IV squamous or nonsquamous NSCLC
  • Participants with nonsquamous NSCLC who are not eligible for an approved targeted therapy
  • Is able to provide sample collected either within 5 years or within the interval from completion of last treatment but before entering the screening period or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated obtained within 90 days of treatment initiation
  • Has not received prior systemic treatment for their NSCLC
  • Is able to complete all screening procedures within the 35-day screening window for Part A and 28-day screening window for Part B

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a diagnosis of small cell lung cancer
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days before the first dose of study treatment
  • Has a known additional that is progressing or has required active treatment within the past 2 years
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has an active disease that has required systemic treatment in the past 2 years
  • Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis
  • Has an active infection requiring systemic therapy
  • Has cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study treatment administration, or Class III or IV congestive heart failure
  • Has a known history of (HIV) infection. Well-controlled HIV with anti-retroviral therapy (ART) is not excluded
  • Has a known history of (HPV) or known active virus infection. Hepatitis B surface antigen (HBsAg) positive is eligible if on HBV antiviral therapy for at least 4 weeks and HBV viral load is undetectable prior to randomization
  • Has had major surgery \<3 weeks before the first dose of study treatment
  • Is expected to require any other form of antineoplastic therapy while on study
  • Has a history or current evidence of a gastrointestinal (GI) condition (e.g. inflammatory bowel disease, Crohn's disease, ulcerative colitis) or impaired liver function or diseases that in the opinion of the investigator may significantly alter the absorption or metabolism of oral medications
  • Is getting chemotherapy and has clinically active diverticulitis, intra-abdominal abscess, GI obstruction, or peritoneal carcinomatosis
  • Has preexisting neuropathy that is moderate in intensity
  • Has received prior systemic cytotoxic chemotherapy or other targeted or biological antineoplastic therapy for metastatic disease
  • Is unable or unwilling to take folic acid or vitamin B12 supplementation, for participants who will receive pemetrexed
  • Has a known sensitivity to any component of carboplatin, paclitaxel, pemetrexed or any of their
  • Has received prior radiation therapy to the lung that is >30 Gray (Gy) within 6 months of the first dose of study treatment
  • Has received a within 30 days before the first dose of study treatment. Any licensed COVID-19 vaccine (including for Emergency Use) in a particular country is allowed as long as they are messenger ribonucleic acid (mRNA) vaccines, adenoviral vaccines, or inactivated vaccines. vaccines (ie, those not licensed or approved for Emergency Use) are not allowed
  • Has received any prior immunotherapy and was discontinued from that treatment due to a severe or worse immune-related adverse event (irAE)
  • Has had chemotherapy or biological cancer therapy within 4 weeks before the first dose of study treatment or has not recovered to (CTCAE) Grade 1 or better from the AEs due to cancer therapeutics administered more than 4 weeks before the first dose of study treatment (including participants who had previous immunomodulatory therapy with residual irAEs)
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study treatment
  • Previously had a severe reaction to treatment with monoclonal antibodies (including pembrolizumab) and/or any of their excipients
  • Has had an allogenic tissue/solid organ transplant
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Part A: Pembrolizumab+Vibostolimab+Carboplatin + Paclitaxel

    On Day 1 of each 3-week cycle, participants with squamous NSCLC receive pembrolizumab 200 mg intravenously (IV) PLUS vibostolimab IV PLUS carboplatin Area Under the Concentration-Time Curve (AUC) 6 IV PLUS paclitaxel 200 mg/m\^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS vibostolimab IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Biological: Vibostolimab

  • Experimental
    Part A: Pembrolizumab+Vibostolimab+Carboplatin + Pemetrexed

    On Day 1 of each 3-week cycle, participants with nonsquamous NSCLC receive pembrolizumab 200 mg IV PLUS vibostolimab IV PLUS carboplatin AUC 5 IV PLUS pemetrexed 500 mg/m\^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS vibostolimab IV PLUS pemetrexed 500 mg/m\^2 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Pemetrexed · Biological: Vibostolimab

  • Experimental
    Part A: Pembrolizumab+Boserolimab+Carboplatin+Paclitaxel

    On Day 1 of each 3-week cycle, participants with squamous NSCLC receive pembrolizumab 200 mg IV PLUS carboplatin AUC 6 IV PLUS paclitaxel 200 mg/m\^2 IV PLUS boserolimab IV on Day 1 every 6 weeks (every other 3-week cycle) (Q6W) in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV Q3W PLUS boserolimab IV Q6W from Cycles 5 up to Cycle 35 (total treatment duration: up to approximately 2 years).

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Biological: Boserolimab

  • Experimental
    Part A: Pembrolizumab+Boserolimab+Carboplatin+Pemetrexed

    On Day 1 of each 3-week cycle, participants with nonsquamous NSCLC receive pembrolizumab 200 mg IV PLUS carboplatin AUC 5 IV PLUS pemetrexed 500 mg/m\^2 IV PLUS boserolimab IV on Day 1 every 6 weeks (every other 3-week cycle) (Q6W) in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV Q3W PLUS pemetrexed 500 mg/m\^2 IV Q3W PLUS boserolimab IV Q6W from Cycles 5 up to Cycle 35 (total treatment duration: up to approximately 2 years).

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Pemetrexed · Biological: Boserolimab

  • Experimental
    Part A: Pembrolizumab+MK-4830+Carboplatin+Paclitaxel

    On Day 1 of each 3-week cycle, participants with squamous NSCLC receive pembrolizumab 200 mg IV PLUS MK-4830 IV PLUS carboplatin AUC 6 IV PLUS paclitaxel 200 mg/m\^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-4830 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Biological: MK-4830

  • Experimental
    Part A: Pembrolizumab+MK-4830+Carboplatin+Pemetrexed

    On Day 1 of each 3-week cycle, participants with nonsquamous NSCLC receive pembrolizumab 200 mg IV PLUS MK-4830 IV PLUS carboplatin AUC 5 IV PLUS pemetrexed 500 mg/m\^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-4830 IV PLUS pemetrexed 500 mg/m\^2 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Pemetrexed · Biological: MK-4830

  • Experimental
    Part A: Pembrolizumab+MK-0482+Carboplatin+Paclitaxel

    On Day 1 of each 3-week cycle, participants with squamous NSCLC receive pembrolizumab 200 mg IV PLUS MK-0482 IV PLUS carboplatin AUC 6 IV PLUS paclitaxel 200 mg/m\^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-0482 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).

    Biological: Pembrolizumab · Drug: Carboplatin · Biological: MK-0482

  • Experimental
    Part A: Pembrolizumab+MK-0482+Carboplatin+Pemetrexed

    On Day 1 of each 3-week cycle, participants with nonsquamous NSCLC receive pembrolizumab 200 mg IV PLUS MK-0482 IV PLUS carboplatin AUC 5 IV PLUS pemetrexed 500 mg/m\^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-0482 IV PLUS pemetrexed 500 mg/m\^2 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).

    Biological: Pembrolizumab · Drug: Carboplatin · Biological: MK-0482

  • Experimental
    Part B: Pembrolizumab + I-DXd

    On Day 1 of each 3-week cycle, participants with squamous and nonsquamous NSCLC will receive pembrolizumab 200 mg IV for up to 2 years, PLUS I-DXd in escalating doses until progressive disease or toxicity.

    Biological: Pembrolizumab · Biological: Ifinatamab Deruxtecan (I-DXd)

  • Experimental
    Part B: Pembrolizumab + Carboplatin + I-DXd

    On Day 1 of each 3-week cycle, participants will receive pembrolizumab 200 mg IV for up to 2 years, PLUS carboplatin AUC 5-6 up to 4 cycles PLUS I-DXd IV in escalating doses until PD or toxicity.

    Biological: Pembrolizumab · Drug: Carboplatin · Biological: Ifinatamab Deruxtecan (I-DXd)

  • Experimental
    Part B: Pembrolizumab + Carboplatin + HER3-DXd

    On Day 1 of each 3-week cycle, participants will receive pembrolizumab 200 mg IV for up to 2 years, PLUS carboplatin AUC 5-6 up to 4 cycles PLUS HER3-DXd IV in escalating doses until PD or toxicity.

    Biological: Pembrolizumab · Drug: Carboplatin · Biological: HER3-DXd

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. ORR will be reported.

    Time frame: Up to approximately 24 months

  2. Part B: Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 27 months

  3. Part B: Number of Participants Who Discontinue Study Intervention Due to an Adverse Event (AE)

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 24 months

  4. Part B: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)

    A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE 5.0). Number of participants who experience a DLT per CTCAE 5.0 will be reported.

    Time frame: Up to approximately 3 Weeks

Secondary outcomes

  1. Part A: Progression-Free Survival (PFS) According to RECIST 1.1

    PFS is defined as the time from first dose of study treatment until either the earliest date of documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS will be reported.

    Time frame: Up to approximately 24 months

  2. Part A: Number of Participants Who Experience One or More AEs

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 27 months

  3. Part A: Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 24 months

  4. Part B: ORR per RECIST 1.1 as assessed by blinded independent central review (BICR)

    ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. ORR will be reported.

    Time frame: Up to approximately 24 months

  5. Part B: Duration of Response (DOR) per RECIST 1.1 as assessed by BICR

    For participants who show confirmed CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. DOR will be reported.

    Time frame: Up to approximately 24 months

  6. Part B: Cmax of I-DXd

    Cmax is the maximum concentration of the drug observed in plasma. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine Cmax of I-DXd.

    Time frame: At designated time points up to approximately 2 years

  7. Part B: Cmax of HER3-DXd

    Cmax is the maximum concentration of the drug observed in plasma. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine Cmax of HER3-DXd.

    Time frame: At designated time points up to approximately 2 years

  8. Part B: Cmax of pembrolizumab

    Cmax is the maximum concentration of the drug observed in serum. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine Cmax of pembrolizumab.

    Time frame: At designated time points up to approximately 2 years

  9. Part B: Ctrough of I-DXd

    Ctrough is defined as the lowest observed concentration of drug in plasma at the end of the dosing interval. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine Ctrough of I-DXd.

    Time frame: At designated time points up to approximately 2 years

  10. Part B: Ctrough of HER3-DXd

    Ctrough is defined as the lowest observed concentration of drug in plasma at the end of the dosing interval. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine Ctrough of HER3-DXd.

    Time frame: At designated time points up to approximately 2 years

  11. Part B: Ctrough of pembrolizumab

    Ctrough is defined as the lowest observed concentration of drug in serum at the end of the dosing interval. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine Ctrough of pembrolizumab.

    Time frame: At designated time points up to approximately 2 years

07

Study locations

16 of 47 sites recruiting
  • Banner MD Anderson Cancer Center ( Site 0001)
    Gilbert, Arizona 85234, United States
    Completed

    Not enrolling at this site — choose another above.

  • City of Hope ( Site 0014)
    Duarte, California 91010, United States
    Completed

    Not enrolling at this site — choose another above.

  • UCSF Medical Center at Mission Bay ( Site 0007)
    San Francisco, California 94158, United States
    Completed

    Not enrolling at this site — choose another above.

  • Georgetown University ( Site 0036)
    Washington D.C., District of Columbia 20007, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Kentucky Markey Cancer Center ( Site 0019)
    Lexington, Kentucky 40536-0293, United States
    Completed

    Not enrolling at this site — choose another above.

  • MedStar Franklin Square Medical Center ( Site 0033)
    Baltimore, Maryland 21237, United States
    Completed

    Not enrolling at this site — choose another above.

  • Massachusetts General Hospital ( Site 0003)
    Boston, Massachusetts 02114, United States
    Completed

    Not enrolling at this site — choose another above.

  • Dana Farber Cancer Institute ( Site 0002)
    Boston, Massachusetts 02215, United States
    Completed

    Not enrolling at this site — choose another above.

  • Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031)
    Omaha, Nebraska 68130, United States
    Completed

    Not enrolling at this site — choose another above.

  • Dartmouth Hitchcock Medical Center ( Site 0016)
    Lebanon, New Hampshire 03766, United States
    Recruiting
    • Study Coordinator · Contact603-650-4428
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037)
    Hackensack, New Jersey 07601, United States
    Completed

    Not enrolling at this site — choose another above.

  • Laura and Isaac Perlmutter Cancer Center ( Site 0034)
    New York, New York 10016, United States
    Completed

    Not enrolling at this site — choose another above.

  • Sanford Fargo Medical Center ( Site 0039)
    Fargo, North Dakota 58102, United States
    Recruiting
    • Study Coordinator · Contact701-234-2000
  • Cleveland Clinic Main ( Site 0006)
    Cleveland, Ohio 44195, United States
    Completed

    Not enrolling at this site — choose another above.

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015)
    Columbus, Ohio 43210, United States
    Recruiting
    • Study Coordinator · Contact614-366-0233
  • Abramson Cancer Center of the University of Pennsylvania ( Site 0010)
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Study Coordinator · Contact215-220-9703
  • Sanford Cancer Center ( Site 0038)
    Sioux Falls, South Dakota 57104, United States
    Recruiting
    • Study Coordinator · Contact605-328-8000
  • The University of Texas MD Anderson Cancer Center ( Site 0009)
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact844-465-0138
  • Cross Cancer Institute ( Site 0291)
    Edmonton, Alberta T6G 1Z2, Canada
    Recruiting
    • Study Coordinator · Contact780-432-8771
  • Petz Aladar Megyei Oktato Korhaz ( Site 0062)
    Győr, Győr-Moson-Sopron 9024, Hungary
    Completed

    Not enrolling at this site — choose another above.

  • Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 0061)
    Szolnok, Jász-Nagykun-Szolnok 5004, Hungary
    Completed

    Not enrolling at this site — choose another above.

  • Orszagos Koranyi Pulmonologiai Intezet ( Site 0060)
    Budapest, 1121, Hungary
    Completed

    Not enrolling at this site — choose another above.

  • Soroka Medical Center ( Site 0072)
    Beersheba, 8457108, Israel
    Completed

    Not enrolling at this site — choose another above.

  • Rambam Health Care Campus-Oncology ( Site 0076)
    Haifa, 3109601, Israel
    Completed

    Not enrolling at this site — choose another above.

  • Shaare Zedek Medical Center ( Site 0075)
    Jerusalem, 9103102, Israel
    Recruiting
    • Study Coordinator · Contact+97225645203
  • Meir Medical Center ( Site 0071)
    Kfar Saba, 4428132, Israel
    Completed

    Not enrolling at this site — choose another above.

  • Rabin Medical Center ( Site 0074)
    Petah Tikva, 4941492, Israel
    Completed

    Not enrolling at this site — choose another above.

  • Chaim Sheba Medical Center ( Site 0070)
    Ramat Gan, 5262000, Israel
    Recruiting
    • Study Coordinator · Contact+97235307096
  • Sourasky Medical Center ( Site 0077)
    Tel Aviv, 6423906, Israel
    Completed

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliera Universitaria Careggi ( Site 0173)
    Florence, Firenze 50134, Italy
    Completed

    Not enrolling at this site — choose another above.

  • IRCCS Ospedale San Raffaele ( Site 0171)
    Milan, 20132, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Policlinico Gemelli di Roma ( Site 0174)
    Roma, 00168, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 0151)
    Warsaw, Masovian Voivodeship 02-781, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
    Gdansk, Pomeranian Voivodeship 80-952, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152)
    Koszalin, West Pomeranian Voivodeship 75-581, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Seoul National University Bundang Hospital ( Site 0081)
    Seongnam-si, Kyonggi-do 13620, South Korea
    Completed

    Not enrolling at this site — choose another above.

  • Severance Hospital ( Site 0080)
    Seoul, 03722, South Korea
    Completed

    Not enrolling at this site — choose another above.

  • Samsung Medical Center ( Site 0082)
    Seoul, 06351, South Korea
    Completed

    Not enrolling at this site — choose another above.

  • ICO L Hospitalet ( Site 0090)
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Universitario Quiron Madrid ( Site 0091)
    Madrid, 28223, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Changhua Christian Hospital ( Site 0181)
    Changhua, 50006, Taiwan
    Recruiting
    • Study Coordinator · Contact+886983901629
  • Taipei Medical University Hospital ( Site 0180)
    Taipei, 110301, Taiwan
    Recruiting
    • Study Coordinator · Contact+886227372181x7810
  • Chang Gung Medical Foundation-Linkou Branch ( Site 0182)
    Taoyuan, 33305, Taiwan
    Recruiting
    • Study Coordinator · Contact+886975368109
  • COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0463)
    Cherkasy, Cherkasy Oblast 18009, Ukraine
    Recruiting
    • Study Coordinator · Contact+380472370123
  • Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0460)
    Ivano-Frankivsk, Ivano-Frankivsk Oblast 76018, Ukraine
    Recruiting
    • Study Coordinator · Contact+380978411455
  • ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 0461)
    Rivne, Rivne Oblast 33010, Ukraine
    Recruiting
    • Study Coordinator · Contact+380362633075
  • Uzhhorod Multispecialty City Clinical Hospital ( Site 0462)
    Uzhhorod, Zakarpattia Oblast 88017, Ukraine
    Recruiting
    • Study Coordinator · Contact+380506847086
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Feb 2032, 145 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 145 months is above that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2019
First posted
Nov 15, 2019
StartActual
Dec 19, 2019
Primary completionEst.
Feb 13, 2032
CompletionEst.
Oct 13, 2032
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Canada
Show site
  • Cross Cancer Institute ( Site 0291) · Edmonton, Canada
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    1 site added — first site in Canada
    Show site
    • Cross Cancer Institute ( Site 0291) · Edmonton, Canada
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04165070
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Nov 15, 2019
Start date
Dec 19, 2019
Primary completion
Feb 13, 2032 (estimated)
Completion
Oct 13, 2032 (estimated)
Last update
Oct 29, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vibostolimab · Boserolimab · Anti-ILT4 Monoclonal Antibody MK-4830 · Rolistobart · Ifinatamab deruxtecan · Patritumab deruxtecan

Start the discussion